103.36
15.93 (18.22%)
| Penutupan Terdahulu | 87.43 |
| Buka | 90.23 |
| Jumlah Dagangan | 2,076,149 |
| Purata Dagangan (3B) | 657,450 |
| Modal Pasaran | 6,566,026,752 |
| Harga / Jualan (P/S) | 12.97 |
| Harga / Buku (P/B) | 18.39 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 13 Feb 2025 - 17 Feb 2025 |
| Margin Keuntungan | -29.48% |
| Margin Operasi (TTM) | -38.21% |
| EPS Cair (TTM) | -2.09 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 126.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 233.98% |
| Nisbah Semasa (MRQ) | 3.32 |
| Aliran Tunai Operasi (OCF TTM) | -242.15 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -101.52 M |
| Pulangan Atas Aset (ROA TTM) | -14.97% |
| Pulangan Atas Ekuiti (ROE TTM) | -49.65% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Blueprint Medicines Corporation | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 4.0 |
| Purata | 2.50 |
|
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 0.89% |
| % Dimiliki oleh Institusi | 104.93% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Lord, Abbett & Co. Llc | 30 Sep 2024 | 1,178,190 |
| Pictet Asset Management Holding Sa | 30 Sep 2024 | 1,166,507 |
| Polar Capital Holdings Plc | 30 Sep 2024 | 877,005 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 151.00 (Wells Fargo, 46.09%) | Beli |
| Median | 130.50 (26.26%) | |
| Rendah | 88.00 (UBS, -14.86%) | Pegang |
| Purata | 128.00 (23.84%) | |
| Jumlah | 7 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 92.93 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Needham | 13 Jan 2025 | 135.00 (30.61%) | Beli | 103.36 |
| 15 Nov 2024 | 135.00 (30.61%) | Beli | 88.69 | |
| Wedbush | 13 Jan 2025 | 124.00 (19.97%) | Beli | 103.36 |
| Stephens & Co. | 02 Jan 2025 | 140.00 (35.45%) | Beli | 87.20 |
| JMP Securities | 09 Dec 2024 | 125.00 (20.94%) | Beli | 94.57 |
| 18 Nov 2024 | 125.00 (20.94%) | Beli | 90.18 | |
| HC Wainwright & Co. | 15 Nov 2024 | 135.00 (30.61%) | Beli | 88.69 |
| 31 Oct 2024 | 135.00 (30.61%) | Beli | 87.51 | |
| JP Morgan | 14 Nov 2024 | 126.00 (21.90%) | Beli | 95.65 |
| Wells Fargo | 31 Oct 2024 | 151.00 (46.09%) | Beli | 87.51 |
| UBS | 24 Oct 2024 | 88.00 (-14.86%) | Pegang | 83.09 |
| Papar semua | ||||
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 12 Jan 2025 | Pengumuman | Blueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued Growth |
| 18 Dec 2024 | Pengumuman | Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
| 07 Dec 2024 | Pengumuman | Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting |
| 30 Oct 2024 | Pengumuman | Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance |
| 16 Oct 2024 | Pengumuman | Blueprint Medicines to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |